LSA
RXRX icon

Leonteq Securities AG’s Recursion Pharmaceuticals RXRX Stock Holding History

Leonteq Securities AG’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.39K Sell
2,560
-20,000
-89% -$66.6K ﹤0.01% 1032
2026
Q1 		$69.3K Sell
22,560
-102,069
-82% -$394K ﹤0.01% 805
2025
Q4 		$510K Buy
124,629
+57,630
+86% +$285K 0.02% 456
2025
Q3 		$327K Buy
66,999
+2,000
+3% +$10.5K 0.01% 502
2025
Q2 		$329K Buy
64,999
+57,569
+775% +$283K 0.01% 460
2025
Q1 		$39.2K Buy
7,430
+2,499
+51% +$18.2K ﹤0.01% 868
2024
Q4 		$33.3K Sell
4,931
-9,804
-67% -$65.9K ﹤0.01% 900
2024
Q3 		$97.1K Buy
14,735
+2,000
+16% +$14.3K 0.01% 627
2024
Q2 		$95.5K Sell
12,735
-4,500
-26% -$39.2K 0.01% 636
2024
Q1 		$172K Buy
+17,235
New +$192K 0.01% 529

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Leonteq Securities AG's RXRX Position: Q2 2026 in Review

Leonteq Securities AG reduced its Recursion Pharmaceuticals (RXRX) stake by 89% in Q2 2026, selling an estimated $66.6K and leaving 2,560 shares worth $9.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1032.

Leonteq Securities AG first reported a position in RXRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $510K in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Leonteq Securities AG held 2,560 shares of Recursion Pharmaceuticals worth $9.39K as of Q2 2026.
  • Leonteq Securities AG sold 20,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $66.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #1032 holding.
  • Leonteq Securities AG first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Leonteq Securities AG's Recursion Pharmaceuticals position peaked at $510K in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.